A Single-cell Transcriptome Study in Patients With Non-Hodgkin's Lymphoma
NCT04434833 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2020-07-07
Summary
Using single-cell RNA sequencing, this study will explore the heterogeneity of lymphoma inside and outside the lymph node, identify tumor specific molecular markers and cell subgroups, explore the differences in tumor microenvironment composition, and provide a basis for diagnosis and precision treatment.
Conditions
- Non Hodgkin Lymphoma
Sponsors & Collaborators
-
Ruijin Hospital
lead OTHER
Eligibility
- Min Age
- 14 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-07-01
- Primary Completion
- 2022-06-30
- Completion
- 2023-06-30
Countries
- China
Study Locations
More Related Trials
-
Shanghai Lymphoma Clinical Cohort
NCT07285174 ·Status: NOT_YET_RECRUITING
-
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma
NCT05078593 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma
NCT04977167 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
NCT05164770 ·Status: UNKNOWN ·Phase: PHASE3
-
Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma
NCT05189782 ·Status: UNKNOWN
-
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
NCT05097443 ·Status: UNKNOWN ·Phase: PHASE3
-
Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
NCT04480099 ·Status: UNKNOWN ·Phase: PHASE2
-
Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients
NCT04164368 ·Status: COMPLETED ·Phase: PHASE2
-
A Real-World Study on Extranodal Lymphoma
NCT06573099 ·Status: NOT_YET_RECRUITING
-
A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma
NCT04923789 ·Status: UNKNOWN
-
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
NCT05557903 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma
NCT05390528 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Genotype-guided Treatment in DLBCL
NCT05351346 ·Status: RECRUITING ·Phase: PHASE3
-
Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
NCT06594432 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT05797948 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
NCT07082686 ·Status: RECRUITING ·Phase: PHASE2
-
Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
NCT06541327 ·Status: RECRUITING
-
Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma
NCT04934579 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
NCT05506410 ·Status: RECRUITING
-
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
NCT04660799 ·Status: COMPLETED ·Phase: PHASE2
-
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
NCT05887726 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
NCT05444322 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04657302 ·Status: COMPLETED ·Phase: PHASE1
-
Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
NCT04481815 ·Status: RECRUITING ·Phase: PHASE2
-
Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
NCT03802955 ·Status: COMPLETED ·Phase: PHASE1